Drugs / KS24.22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01127074 | Mar 2002 → Jul 2008 | breast cancer | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KS24.22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01127074 ↗ |
| Modality | Vaccine | “the CD80+ HER-2/neu-overexpressing KS variant is actually used as a cellular vaccine in patients with metastatic breast cancer” PMID 15365776 ↗ Sep 2004 |